{"id":12244,"date":"2026-07-20T09:30:00","date_gmt":"2026-07-20T13:30:00","guid":{"rendered":"https:\/\/progresso.com.br\/?p=12244"},"modified":"2026-07-20T08:48:40","modified_gmt":"2026-07-20T12:48:40","slug":"anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin","status":"publish","type":"post","link":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/","title":{"rendered":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Produto biol\u00f3gico \u00e9 indicado para pacientes adultos recidivantes ou ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco<a href=\"https:\/\/facebook.com\/sharer.php?text=%C3%89%20not%C3%ADcia%20na%20AG%C3%8ANCIA%20GOV&amp;u=https:\/\/agenciagov.ebc.com.br\/noticias\/202607\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\" target=\"_blank\" rel=\"noreferrer noopener\">\u00a0<\/a><a href=\"https:\/\/twitter.com\/intent\/tweet?text=%C3%89%20not%C3%ADcia%20na%20AG%C3%8ANCIA%20GOV:%20https:\/\/agenciagov.ebc.com.br\/noticias\/202607\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\" target=\"_blank\" rel=\"noreferrer noopener\">\u00a0<\/a><a href=\"https:\/\/t.me\/share\/url?url=https:\/\/agenciagov.ebc.com.br\/noticias\/202607\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin&amp;text=%C3%89%20not%C3%ADcia%20na%20AG%C3%8ANCIA%20GOV:%20Anvisa%20aprova%20novo%20medicamento%20para%20linfoma%20n%C3%A3o%20Hodgkin\">\u00a0<\/a><\/em><\/strong><a href=\"https:\/\/api.whatsapp.com\/send?text=%C3%89%20not%C3%ADcia%20na%20AG%C3%8ANCIA%20GOV%0a%0aAcesse%20o%20link:%20https:\/\/agenciagov.ebc.com.br\/noticias\/202607\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\">\u00a0<\/a><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https:\/\/agenciagov.ebc.com.br\/noticias\/202607\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin&amp;title=Anvisa%20aprova%20novo%20medicamento%20para%20linfoma%20n%C3%A3o%20Hodgkin&amp;summary=Produto%20biol%C3%B3gico%20%C3%A9%20indicado%20para%20pacientes%20adultos%20recidivantes%20ou%20ineleg%C3%ADveis%20ao%20transplante%20aut%C3%B3logo%20de%20c%C3%A9lulas-tronco&amp;source=Ag%C3%AAncia%20Gov\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Ag\u00eancia Gov | Via Anvisa<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira&nbsp;(20\/7) o registro&nbsp;do medicamento&nbsp;Columvi&nbsp;(glofitamabe).&nbsp;O produto,&nbsp;em combina\u00e7\u00e3o com gencitabina e oxaliplatina,&nbsp;\u00e9 indicado para&nbsp;pacientes adultos com linfoma difuso de grandes c\u00e9lulas B n\u00e3o especificado (LDGCB NOS) recidivante ou refrat\u00e1rio,&nbsp;ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco (TACT).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O linfoma difuso de grandes c\u00e9lulas B \u00e9 o subtipo mais comum de linfoma n\u00e3o Hodgkin agressivo, caracterizado por evolu\u00e7\u00e3o cl\u00ednica r\u00e1pida e necessidade de tratamento eficaz, especialmente em pacientes com doen\u00e7a recidivante ou refrat\u00e1ria e op\u00e7\u00f5es de tratamento limitadas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O registro do&nbsp;Columvi&nbsp;representa uma inova\u00e7\u00e3o terap\u00eautica relevante na \u00e1rea de oncologia hematol\u00f3gica, ao disponibilizar no Brasil um anticorpo&nbsp;biespec\u00edfico&nbsp;capaz de redirecionar o sistema imune contra c\u00e9lulas tumorais . O novo medicamento amplia as op\u00e7\u00f5es de tratamento para pacientes com linfoma agressivo em cen\u00e1rio de necessidade cl\u00ednica.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O medicamento&nbsp;\u00e9 um anticorpo monoclonal&nbsp;biespec\u00edfico&nbsp;humanizado que atua por meio da liga\u00e7\u00e3o simult\u00e2nea ao ant\u00edgeno CD20 presente nas c\u00e9lulas B tumorais e ao CD3 expresso nas c\u00e9lulas T. Esse mecanismo promove a ativa\u00e7\u00e3o das c\u00e9lulas T e a destrui\u00e7\u00e3o direcionada das c\u00e9lulas tumorais.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Produto biol\u00f3gico \u00e9 indicado para pacientes adultos recidivantes ou ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco\u00a0\u00a0\u00a0\u00a0 Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira&nbsp;(20\/7) o registro&nbsp;do medicamento&nbsp;Columvi&nbsp;(glofitamabe).&nbsp;O produto,&nbsp;em combina\u00e7\u00e3o com gencitabina e oxaliplatina,&nbsp;\u00e9 indicado para&nbsp;pacientes adultos com linfoma difuso de grandes c\u00e9lulas B n\u00e3o especificado (LDGCB NOS) recidivante ou [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":12245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,2],"tags":[],"class_list":["post-12244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cotidiano","category-destaque"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO\" \/>\n<meta property=\"og:description\" content=\"Produto biol\u00f3gico \u00e9 indicado para pacientes adultos recidivantes ou ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco\u00a0\u00a0\u00a0\u00a0 Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira&nbsp;(20\/7) o registro&nbsp;do medicamento&nbsp;Columvi&nbsp;(glofitamabe).&nbsp;O produto,&nbsp;em combina\u00e7\u00e3o com gencitabina e oxaliplatina,&nbsp;\u00e9 indicado para&nbsp;pacientes adultos com linfoma difuso de grandes c\u00e9lulas B n\u00e3o especificado (LDGCB NOS) recidivante ou [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\" \/>\n<meta property=\"og:site_name\" content=\"O PROGRESSO\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T13:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"819\" \/>\n\t<meta property=\"og:image:height\" content=\"511\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Rose\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Rose\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\"},\"author\":{\"name\":\"Rose\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\"},\"headline\":\"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin\",\"datePublished\":\"2026-07-20T13:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg\",\"articleSection\":[\"Cotidiano\",\"Em destaque\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\",\"url\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\",\"name\":\"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg\",\"datePublished\":\"2026-07-20T13:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg\",\"width\":819,\"height\":511,\"caption\":\"Envato Novo medicamento amplia op\u00e7\u00f5es de tratamento para pacientes com linfoma agressivo em cen\u00e1rio de necessidade cl\u00ednica. Foto: Divulga\u00e7\u00e3o\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/progresso.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/progresso.com.br\/#website\",\"url\":\"https:\/\/progresso.com.br\/\",\"name\":\"O PROGRESSO\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/progresso.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/progresso.com.br\/#organization\",\"name\":\"O PROGRESSO\",\"url\":\"https:\/\/progresso.com.br\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"width\":1960,\"height\":1080,\"caption\":\"O PROGRESSO\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\",\"https:\/\/www.instagram.com\/oprogresso_digital\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\",\"name\":\"Rose\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"caption\":\"Rose\"},\"url\":\"https:\/\/progresso.com.br\/index.php\/author\/rose\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO","og_description":"Produto biol\u00f3gico \u00e9 indicado para pacientes adultos recidivantes ou ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco\u00a0\u00a0\u00a0\u00a0 Ag\u00eancia Gov | Via Anvisa A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) publicou nesta segunda-feira&nbsp;(20\/7) o registro&nbsp;do medicamento&nbsp;Columvi&nbsp;(glofitamabe).&nbsp;O produto,&nbsp;em combina\u00e7\u00e3o com gencitabina e oxaliplatina,&nbsp;\u00e9 indicado para&nbsp;pacientes adultos com linfoma difuso de grandes c\u00e9lulas B n\u00e3o especificado (LDGCB NOS) recidivante ou [&hellip;]","og_url":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/","og_site_name":"O PROGRESSO","article_publisher":"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","article_published_time":"2026-07-20T13:30:00+00:00","og_image":[{"width":819,"height":511,"url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg","type":"image\/jpeg"}],"author":"Rose","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Rose","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#article","isPartOf":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/"},"author":{"name":"Rose","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b"},"headline":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin","datePublished":"2026-07-20T13:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg","articleSection":["Cotidiano","Em destaque"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/","url":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/","name":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin - O PROGRESSO","isPartOf":{"@id":"https:\/\/progresso.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg","datePublished":"2026-07-20T13:30:00+00:00","breadcrumb":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#primaryimage","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/07\/saude.jpg","width":819,"height":511,"caption":"Envato Novo medicamento amplia op\u00e7\u00f5es de tratamento para pacientes com linfoma agressivo em cen\u00e1rio de necessidade cl\u00ednica. Foto: Divulga\u00e7\u00e3o"},{"@type":"BreadcrumbList","@id":"https:\/\/progresso.com.br\/index.php\/2026\/07\/20\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/progresso.com.br\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin"}]},{"@type":"WebSite","@id":"https:\/\/progresso.com.br\/#website","url":"https:\/\/progresso.com.br\/","name":"O PROGRESSO","description":"","publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/progresso.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/progresso.com.br\/#organization","name":"O PROGRESSO","url":"https:\/\/progresso.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","width":1960,"height":1080,"caption":"O PROGRESSO"},"image":{"@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","https:\/\/www.instagram.com\/oprogresso_digital"]},{"@type":"Person","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b","name":"Rose","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","caption":"Rose"},"url":"https:\/\/progresso.com.br\/index.php\/author\/rose\/"}]}},"_links":{"self":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/12244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/comments?post=12244"}],"version-history":[{"count":1,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/12244\/revisions"}],"predecessor-version":[{"id":12246,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/12244\/revisions\/12246"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media\/12245"}],"wp:attachment":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media?parent=12244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/categories?post=12244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/tags?post=12244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}